EMA Guideline on Development and Manufacture of Synthetic Peptides

Summary

The European Medicines Agency (EMA) finalized its “Guideline on the Development and Manufacture of Synthetic Peptides,” adopted in December 2025 (reference: EMA/CHMP/CVMP/QWP/367182/2025) with an effective date of June 1, 2026. This guideline establishes comprehensive quality requirements for synthetic peptides intended as pharmaceutical products in the EU, covering manufacturing process controls, impurity profiling, characterization, and lifecycle management.

Background

Scope

The guideline addresses aspects of synthetic peptide manufacturing not covered by the existing “Guideline on the Chemistry of Active Substances,” including:

• Manufacturing process controls and validation
• Characterization and structural confirmation
• Specifications and analytical control strategies
• Conjugation requirements (for peptide conjugates)
• Medicinal product development considerations
• Synthetic peptides developed using biological peptides as European reference medicinal products
• Clinical trial applications (human products only)

Key requirements:

1. Orthogonal characterization: At least two orthogonal analytical methods must be used to confirm peptide sequence and purity
2. Impurity profiling: Full identification and control of synthesis-related impurities, degradation products, and process-related impurities
3. Manufacturing process control: Manufacturers must demonstrate control over each synthesis step, reagent quality, and degradation pathways
4. Lifecycle management: Ongoing stability programs and trend analysis required

What it does NOT cover:

• Research peptides are explicitly excluded — compounds used in non-clinical or early research settings are not subject to these pharmaceutical manufacturing requirements
• Does not regulate the research peptide supply chain
• Does not apply to peptides that are not seeking marketing authorization in the EU

Impact

• Raises the bar for EU pharmaceutical peptides: Manufacturers seeking marketing authorization for synthetic peptide drugs must meet these new quality standards
• Does not directly affect research peptides: The explicit exclusion of research-use peptides means this guideline does not change the legal landscape for research peptide vendors
• Harmonization signal: The EMA’s move suggests that global regulatory bodies are converging on stricter peptide manufacturing standards
• Cost implications: Compliance will increase manufacturing costs for pharmaceutical-grade peptides, potentially widening the price gap between pharma-grade and research-grade products
• Biosimilar pathway: The guideline addresses synthetic peptides developed using biological peptides as reference products, clarifying the pathway for peptide biosimilar development in the EU

What This Means for Researchers

• Research peptide users are not directly affected by this guideline — it applies only to peptides seeking EU marketing authorization
• However, the guideline signals the direction of travel: regulatory bodies are increasingly focused on peptide quality and manufacturing standards
• Researchers using synthetic peptides for clinical trial applications in the EU will need to comply with these requirements
• The explicit exclusion of research peptides may provide some regulatory clarity in the EU context, distinguishing the research market from the pharmaceutical market
• EU-based researchers should be aware that domestic peptide suppliers may face increased scrutiny even if this guideline does not directly apply to them

Sources

• EMA — Development and Manufacture of Synthetic Peptides (Scientific Guideline)
• EMA — Guideline Document (PDF)
• LSC Group — Synthetic Peptide EMA Guidance
• American Peptide — Europe’s New Peptide Guidelines
• PrimeGen Labs — Peptide Regulations 2026